Document Detail


Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.
MedLine Citation:
PMID:  19357103     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
During the period of November 2007 to January 2008, an increased prevalence of adverse reactions to heparin was noted. These adverse events have been attributed to the presence of purposeful contaminant, oversulfated chondroitin sulfate (OSCS) from April 2007 to May 2008. An analysis of dialysis patients' plasma obtained in 2006 and 2007 consistently had a low (5%) prevalence of AHPF4 antibodies. Blood samples from 78 patients on maintenance hemodialysis, who were potentially exposed to OSCS-contaminated heparin, were analyzed for the presence of all AHPF4 antibodies using a commercially available ELISA kit from GTI. Although there was no change in the platelet count of these patients, 15 of 78 patients (19.2%) studied had an increased prevalence of AHPF4 antibodies. Subtyping of the all platelet factor 4 (PF4) antibodies documented showed a higher prevalence of immunoglobulin G antibodies as compared to their previously determined antibodies. These observations suggest that the OSCS contaminant in the recalled heparin triggers an immunogenic response not seen with OSCS-contaminated free heparin.
Authors:
Cafer Adiguzel; Vinod Bansal; Evangelos Litinas; Josephine Cunanan; Omer Iqbal; Kelly Nelson; Meganathan Kannan; Debra Hoppensteadt; Jawed Fareed
Related Documents :
17525363 - Effects of unfractionated heparin and glycoprotein iib/iiia antagonists versus bivalird...
2847353 - Immediate effects of heparin and lmw heparin on some platelet and endothelial derived f...
10148313 - First results obtained in france with the latest model of the fresenius cell separator:...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis     Volume:  15     ISSN:  1076-0296     ISO Abbreviation:  Clin. Appl. Thromb. Hemost.     Publication Date:    2009 Mar-Apr
Date Detail:
Created Date:  2009-04-09     Completed Date:  2009-09-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508125     Medline TA:  Clin Appl Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  145-51     Citation Subset:  IM    
Affiliation:
Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Autoantibodies / blood*,  immunology
Carbon Radioisotopes
Chondroitin Sulfates / administration & dosage,  poisoning*
Drug Contamination*
Enzyme-Linked Immunosorbent Assay
Heparin / administration & dosage,  chemistry*
Humans
Immunoglobulin G / blood,  immunology
Kidney Failure, Chronic / blood,  therapy
Platelet Aggregation / drug effects
Platelet Count
Platelet Factor 4 / immunology*
Renal Dialysis / adverse effects
Serotonin / metabolism
Thrombocytopenia / blood*,  chemically induced,  immunology
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Carbon Radioisotopes; 0/Immunoglobulin G; 37270-94-3/Platelet Factor 4; 50-67-9/Serotonin; 9005-49-6/Heparin; 9007-28-7/Chondroitin Sulfates

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Structural and Functional Characterization of Low-molecular-weight Heparins: Impact on the Developme...
Next Document:  Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms f...